NCT04764617

Brief Summary

As people get older, the amount of skeletal muscle in the body can decrease. When the amount of this muscle in the body gets very low, there is an increased risk of falling, and not only is recovery to any injury slower, but more complications can be experienced following surgery, and patients may end up being more dependent on the help of others for meeting daily activities. However, it is not clear whether it is simply the amount of muscle that is in the body that is important for health, or whether it is the ability of muscle to function properly which is important. This research study is looking at the way muscles of frail older people function; not just how strong they are, but the amount of fats and protein that there are in muscle cells, and how the genes in the muscles are being expressed (genes being a collection of chemical information that carry the instructions for making the proteins a cell will need to function). We will also investigate whether recovery from hip fracture is impacted by the amount of muscle that there is in the body, and/or the functioning of this muscle.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 4, 2021

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

February 8, 2021

Completed
13 days until next milestone

First Posted

Study publicly available on registry

February 21, 2021

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

April 1, 2026

Status Verified

August 1, 2025

Enrollment Period

4 years

First QC Date

February 8, 2021

Last Update Submit

March 26, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Skeletal Muscle messenger ribonucleic acid (mRNA) expression (injured leg)

    mRNA expression of 384 gene targets spanning a number of cellular functions, in a vastus lateralis muscle biopsy taken from the injured leg

    On recruitment

Secondary Outcomes (23)

  • Skeletal Muscle mRNA expression (un-injured leg)

    On recruitment

  • Intramyocellular lipid density (injured leg)

    On recruitment

  • Intramyocellular lipid density (uninjured leg)

    On recruitment

  • Body weight

    on recruitment

  • Grip Strength

    up to 3 days post surgery

  • +18 more secondary outcomes

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Individuals \>65 years who have been admitted to Queens Medical Centre, Nottingham, UK for surgical repair of a hip fracture sustained following a low impact fall.

You may qualify if:

  • Clinical Frailty Score (assessed as part of standard care) ≥ 4
  • Fractured hip, sustained following a fall, that requires surgery
  • Good understanding of spoken and written English language
  • Able to give informed consent, or availability of a legally acceptable surrogate to provide consent

You may not qualify if:

  • Those who fell and sustained their hip fracture greater than 12 hours prior to hospitalisation.
  • Those who have fallen and sustained a hip fracture whilst an in-patient in hospital
  • Those who sustained the hip fracture as a result of high impact trauma (e.g. road traffic accident)
  • Surgery carried out later than 96 hrs after fall
  • Chronic neurological, inflammatory or musculoskeletal disorders which result in muscle wasting, e.g. Multiple sclerosis, muscular dystrophy, rheumatoid arthritis
  • Any co-morbidity which precludes hip surgery
  • Those with a compromised swallowing reflex which would prevent the participant from taking fluids orally, will be excluded.
  • Those taking diabetes medication

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Queens Medical Centre; Department of Orthopaedics

Nottingham, NG72UH, United Kingdom

Location

Biospecimen

Retention: SAMPLES WITH DNA

Skeletal Muscle biopsy

MeSH Terms

Conditions

Frailty

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Ben Ollivere, MBBS

    University of Nottingham

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 8, 2021

First Posted

February 21, 2021

Study Start

January 4, 2021

Primary Completion

December 31, 2024

Study Completion

December 31, 2025

Last Updated

April 1, 2026

Record last verified: 2025-08

Locations